Welcome to our dedicated page for Ribbon Acquisition news (Ticker: RIBBU), a resource for investors and traders seeking the latest updates and insights on Ribbon Acquisition stock.
Ribbon Acquisition Corp (NASDAQ: RIBBU) is a blank check company formed to pursue a business combination with one or more businesses or entities. Its news flow reflects both its capital markets activity as a SPAC and its progress toward identifying and executing a transaction. Press releases describe its initial public offering of units on The Nasdaq Capital Market, with each unit consisting of one Class A ordinary share and one right to receive one-seventh of one Class A ordinary share upon consummation of an initial business combination.
A key development reported in company news and SEC filings is the announcement of a Business Combination Agreement with DRC Medicine Inc., DRC Medicine Ltd., and DRC Merger Inc. This proposed transaction would involve a share exchange, a domestication of Ribbon from the Cayman Islands to Delaware, and a merger in which Ribbon will be combined with a merger subsidiary that remains a wholly owned subsidiary of PubCo. Related news coverage also highlights that, upon completion of the proposed transaction, DRC Medicine is expected to become a publicly traded company listed on the Nasdaq Global Market.
Investors following RIBBU news can review updates on the IPO, listing details for units, Class A ordinary shares and rights, and announcements related to the proposed business combination, including transaction structure, conditions to closing, and regulatory filings such as the planned Form S-4 registration statement and proxy statement/prospectus. News items also describe DRC Medicine’s business focus on AI-powered allergy and infection diagnostic kits and protective face masks, providing context on the nature of the target business associated with Ribbon’s proposed transaction.
This page aggregates Ribbon Acquisition Corp news so readers can track official announcements, transaction milestones, and regulatory communication relating to the SPAC and its proposed combination with DRC Medicine.
DRC Medicine Ltd. and Ribbon Acquisition Corp. (NASDAQ: RIBBU) have announced a business combination agreement that will result in DRC Medicine becoming a publicly traded company. The transaction implies a pro forma equity value of $422.15 million and is expected to provide $50.42 million in cash proceeds (assuming no redemptions).
DRC Medicine, a Japanese healthcare and biotechnology company, specializes in proprietary Hydro Silver Titanium® technology for therapeutic masks targeting seasonal allergic rhinitis. The company is also developing In Vitro Diagnostic (IVD) kits for infectious diseases and allergen detection, utilizing AI-powered applications and cell-free protein synthesis technology. Additionally, DRC Medicine is in final negotiations to acquire a company developing an ATP-enhancing drug for Parkinson's disease.
Under the agreement terms, current DRC Medicine shareholders will maintain 100% of their equity and own approximately 82.91% of the combined company on a pro forma basis. The transaction implies a pre-money equity value of $350 million for DRC on a fully diluted basis.
Ribbon Acquisition Corp (NASDAQ: RIBBU) has announced that holders of its 5,000,000 units from the initial public offering can now separately trade the ordinary shares and rights included in these units, effective March 7, 2025.
The units will continue trading on the Nasdaq Capital Market under the symbol 'RIBBU', while the separated components will trade under 'RIBB' for ordinary shares and 'RIBBR' for rights. Unit holders seeking to separate their units must have their brokers contact Odyssey Trust Company, the company's transfer agent.
Ribbon Acquisition Corp (NASDAQ: RIBBU) has successfully completed its initial public offering (IPO) of 5,000,000 units at $10.00 per unit, raising $50 million. Each unit comprises one Class A ordinary share and one right to receive one-seventh of one Class A ordinary share upon completing an initial business combination.
The units began trading on NASDAQ under 'RIBBU' on January 15, 2025. The ordinary shares and rights will later trade separately under 'RIBB' and 'RIBBR' respectively. A.G.P./Alliance Global Partners served as the sole book-running manager, with The Benchmark Company as co-manager. The underwriters have a 45-day option to purchase up to 750,000 additional units to cover over-allotments.
Ribbon Acquisition Corp, a Cayman Islands-based blank check company, has announced the pricing of its initial public offering (IPO) of 5,000,000 units at $10.00 per unit. Each unit comprises one Class A ordinary share and one right to receive one-seventh of one Class A ordinary share upon completing an initial business combination.
The units will trade on Nasdaq under the symbol 'RIBBU' starting January 15, 2025, with the IPO expected to close around January 16, 2025. Once separate trading begins, the Class A shares and rights will trade under 'RIBB' and 'RIBBR' respectively.
A.G.P./Alliance Global Partners is the sole book-running manager, with The Benchmark Company as co-manager. The underwriters have a 45-day option to purchase up to 750,000 additional units to cover over-allotments.